Nuvectis Pharma, Inc. — Director's Dealing 2023

Oct 6, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Nuvectis Pharma, Inc. (NVCT)
CIK: 0001875558
Period of Report: 2023-10-04

Reporting Person: BENTSUR RON (Director, Chairman & CEO, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-10-04	Common Stock	P	1820	$10.95	Acquired	3234364	Direct
2023-10-05	Common Stock	P	1400	$11.09	Acquired	3235764	Direct

Footnotes

F1: Reflects the weighted average purchase price. The range of prices for the shares purchased was $10.76 to $11.236. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price.

F2: Includes 426,759 shares of restricted stock.

F3: Reflects the weighted average purchase price. The range of prices for the shares purchased was $10.7875 to $11.32. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price.